Zhejiang Yatai Pharmaceutical Co.Ltd(002370)
Simplified equity change report
Name of listed company: Zhejiang Yatai Pharmaceutical Co.Ltd(002370) stock listing place: Shenzhen Stock Exchange Stock abbreviation: Zhejiang Yatai Pharmaceutical Co.Ltd(002370) Stock Code: 002370 information disclosure obligor: Bank Of Ningbo Co.Ltd(002142) Shaoxing Branch domicile: No. 653 Jiefang Avenue, Shaoxing City nature of share change: share reduction (agreement transfer) signing date: January 11, 2002
Statement of information disclosure obligor
1、 The information disclosure obligor shall, in accordance with the securities law of the people’s Republic of China (hereinafter referred to as the “Securities Law”), the measures for the administration of the acquisition of listed companies (hereinafter referred to as the “acquisition measures”), the standards for the contents and forms of information disclosure by companies offering securities to the public No. 15 – Report on changes in equity and other laws This report is prepared by laws, regulations and normative documents. 2、 The information disclosure obligor has obtained necessary authorization and approval for signing this report, and its performance does not violate or conflict with any provision in the articles of association or internal rules of the information disclosure obligor.
3、 In accordance with the provisions of the securities law and the acquisition measures, this report has fully disclosed the changes in the shares in which the information disclosure obligor has an interest in Zhejiang Yatai Pharmaceutical Co.Ltd(002370) ;
As of the signing date of this report, except for the information disclosed in this report, the information disclosure obligor has not increased or reduced its shares in Zhejiang Yatai Pharmaceutical Co.Ltd(002370) by any other means. 4、 This equity change is based on the information stated in this report. Except for the information disclosure obligor, no other person has been entrusted or authorized to provide information not listed in this report and make any explanation or explanation to this report.
5、 The information disclosure obligor promises that there are no false records, misleading statements or major omissions in this report, and will bear individual and joint legal liabilities for its authenticity, accuracy and completeness.
catalogue
Section 1 interpretation Section 2 Introduction to information disclosure obligors Section III purpose of equity change Section IV equity change method 8 section V Trading of listed shares in the first six months Section VI other major matters Section 7 documents for future reference eleven
Section I interpretation
In this report, unless otherwise stated, the following abbreviations are interpreted in this report as follows: Zhejiang Yatai Pharmaceutical Co.Ltd(002370) . Listed company
Refers to Zhejiang Yatai Pharmaceutical Co.Ltd(002370)
Company, company
Bank Of Ningbo Co.Ltd(002142) Shaoxing issue, hereinafter referred to as Bank Of Ningbo Co.Ltd(002142) Shaoxing information disclosure obligor refers to
branch
Asia Pacific Group means Zhejiang Asia Pacific Group Co., Ltd
Fubon group refers to Ningbo Fubang Jingye Group Co.Ltd(600768) Holding Group Co., Ltd
This report and this report refer to the equity change in the Zhejiang Yatai Pharmaceutical Co.Ltd(002370) short form equity change report, which refers to the equity change due to the change of information disclosure obligor due to the transfer of equity by agreement and the reduction of shareholding proportion in this change
Exchange and Shenzhen Stock Exchange refer to Shenzhen Stock Exchange
CSRC refers to the China Securities Regulatory Commission
Yuan and 10000 yuan refer to RMB yuan and 10000 yuan
Section II introduction to information disclosure obligors
1、 Basic information of information disclosure obligor
1. Name: Bank Of Ningbo Co.Ltd(002142) Shaoxing Branch
2. Registered address: No. 653, Jiefang Avenue, Shaoxing
3. Legal representative: Chen Xin
4. Registered capital:/
5. Unified social credit Code: 9133060009768p
6. Enterprise type: branch of joint stock limited company (Sino foreign joint venture, listed)
7. Business scope: absorbing public deposits; Issuing short-term, medium-term and long-term loans; Handle settlement outside China; Handle bill acceptance and discount; Acting as an agent for issuing and cashing government bonds; Engage in bank card business; Provide letter of credit services; Agent collection and payment; Operate the business authorized by the head office within the business scope approved by the Bank Of China Limited(601988) Industry Regulatory Commission. (for projects subject to approval according to law, business activities can be carried out only after approval by relevant departments)
8. Term of operation: long term
The information discloser is a subsidiary of Bank Of Ningbo Co.Ltd(002142) . The shareholders and main principals of Bank Of Ningbo Co.Ltd(002142) are as follows:
Top ten shareholders by September 30, 2021:
No. shareholder name holding proportion (%)
1 Ningbo Development and Investment Group Co., Ltd. 18.72
2 OVERSEA-CHINESE BANKING CORPORATION LIMITED 18.67
3 Youngor Group Co.Ltd(600177) 8.32
4 Hong Kong Central Clearing Company Limited 5.53
5 Huamao Group Co., Ltd. 2.66
6 Ningbo Fubang Jingye Group Co.Ltd(600768) Holding Group Co., Ltd. 1.84
7 overseas Chinese Bank Co., Ltd. 1.33
8 Ningxing (Ningbo) Asset Management Co., Ltd. 1.29
9 Ningbo Rail Transit Group Co., Ltd. 1.18
Huijin central Asset Management Co., Ltd
Directors and main responsible persons:
Whether it has obtained information from other countries or positions
Name Gender nationality right of abode
Lu Huayu, male, chairman of China
Shi tingjun, male, director of China
Wei Xuemei, female director of China
Chen Shouping, male, is a director of Singapore
Zhu nianhui, male, is a director of Singapore
Liu Xinyu, female, director of China
Feng peijiong, male, director and vice president of China
Zhuang Lingjun, male, director, vice president and financial director of China
Hu Pingxi, male, independent director of China
Is Mr. betto Guangnan an independent director of China
Li Haonan: is China an independent director
Hong Peili: is she an independent director of China
Wang Wei’an, male, independent director of China
2、 Information disclosure obligor’s equity shares in other domestic and overseas listed companies reach or exceed 5% of the issued shares of the company
As of the signing date of this report, except for holding Zhejiang Yatai Pharmaceutical Co.Ltd(002370) 39 million shares, the information disclosure obligor does not have shares with interests in other domestic and overseas listed companies that reach or exceed 5% of the issued shares of the company.
Section III purpose of shareholding change
1、 Purpose of equity change of information disclosure obligor
This equity change is mainly due to the signing of the share transfer agreement between the information disclosure obligor and Fubon group and the transfer of 39 million Zhejiang Yatai Pharmaceutical Co.Ltd(002370) shares held by Fubon group.
According to the court’s ruling, the information disclosure obligor obtained Zhejiang Yatai Pharmaceutical Co.Ltd(002370) 39 million equity shares by paying off debts in kind (see the short form equity change report on June 24, 2021 for details). Due to the management requirement that the debt paying assets related to the banking industry should be disposed of within 2 years, the information disclosure obligor accepted the purchase application of Fubon group and agreed to transfer 39 million Zhejiang Yatai Pharmaceutical Co.Ltd(002370) shares to Fubon group at the price of 203.19 million yuan. After the completion of this transaction, the information disclosure obligor will no longer hold Zhejiang Yatai Pharmaceutical Co.Ltd(002370) shares, and the equity change proportion will reach more than 5% of the total share capital of Zhejiang Yatai Pharmaceutical Co.Ltd(002370) .
2、 Shareholding plan of information disclosure obligor in the next 12 months
After the equity change, the information disclosure obligor has no plan to increase its shares in the company in the next 12 months.
In case of any change in relevant rights and interests, the information disclosure obligor will perform the information disclosure obligation in strict accordance with relevant laws and regulations.
Section IV changes in equity
1、 Shareholding of information disclosure obligor before and after shareholding change
Before this equity change, the information disclosure obligor held Zhejiang Yatai Pharmaceutical Co.Ltd(002370) 39 million shares, which was due to the execution of the court ruling to obtain Zhejiang Yatai Pharmaceutical Co.Ltd(002370) shares by means of debt repayment, accounting for 7.27% of the total share capital of Zhejiang Yatai Pharmaceutical Co.Ltd(002370) .
After this equity change, the information disclosure obligor no longer holds Zhejiang Yatai Pharmaceutical Co.Ltd(002370) shares.
2、 Main changes in equity
On January 10, 2022, Bank Of Ningbo Co.Ltd(002142) Shaoxing Branch signed a share transfer agreement with Fubon group through consultation between Fubon group and the information disclosure obligor, agreeing to transfer 39 million Zhejiang Yatai Pharmaceutical Co.Ltd(002370) shares held by Fubon group at a price of 5.21 yuan / share, totaling 203.19 million yuan. Both parties agreed to pay 10% of all share transfer funds as a deposit within 3 working days from the date of signing the agreement, The deposit shall be converted into the transaction price after the transfer of the subject shares is completed, and the balance shall be paid within 5 working days from the date of completion of the share transfer registration. This transaction shall be subject to the compliance review of Shenzhen Stock Exchange, and the transaction transfer can be handled only after passing the review. If this transaction is completed, the information disclosure obligor will no longer hold Zhejiang Yatai Pharmaceutical Co.Ltd(002370) shares.
Section V Trading of listed shares in the first six months
The information disclosure obligor did not buy or sell Zhejiang Yatai Pharmaceutical Co.Ltd(002370) shares through the centralized trading of the stock exchange within six months before the date of signing this report.
Section VI other major matters
1、 Other matters to be disclosed
As of the signing date of this report, the information disclosure obligor has truthfully disclosed the information related to this equity change in accordance with relevant regulations, and there are no other information that must be disclosed according to the application of law and in order to avoid misunderstanding of the content of this report, as well as other major information that should be disclosed but not disclosed by the information disclosure obligor.
2、 Statement of information disclosure obligor
The information disclosure obligor promises that there are no false records, misleading statements or major omissions in this report, and will bear individual and joint legal liabilities for its authenticity, accuracy and completeness.
Section VII documents for future reference
1、 A copy of the business license or identity document of the information disclosure obligor;
2、 Share transfer agreement related to this equity change;
3、 A simplified equity change report signed by the information disclosure obligor;
4、 Other documents for future reference required by CSRC or Shenzhen Stock Exchange.
The full text of this report and the above documents for future reference are placed in Zhejiang Yatai Pharmaceutical Co.Ltd(002370) securities investment department.
Appendix basic information of short form equity change report
Name of listed company Zhejiang Zhejiang Yatai Pharmaceutical Co.Ltd(002370) Co., Ltd
Limited company in place
Stock abbreviation Zhejiang Yatai Pharmaceutical Co.Ltd(002370) stock code 002370
Information disclosure obligor Bank Of Ningbo Co.Ltd(002142) Co., Ltd. information disclosure Yi Shaoxing Jiefang Avenue 653 name department Shaoxing Branch agent registration No
Increase □ decrease ■ no consistent line □ no ■
The quantity changes, but the shareholder changes
